Physician profile
John Mckee
NPI 1972503456
$4,375.50
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $324 · 2021: $546 · 2022: $196 · 2023: $608 · 2024: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,291 · Travel and Lodging: $1,125 · Education: $22.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.99 |
| Travel and Lodging | $1,124.71 |
| Education | $22.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,388.28 | 2019-2024 | |
| Abbott Laboratories | $1,319.70 | 2024 | Mitraclip |
| Intercept Pharmaceuticals, INC. | $293.30 | 2020-2024 | Ocaliva |
| Pfizer INC. | $125.01 | 2019 | |
| Csl Behring | $121.51 | 2024 | Kcentra |
| Pentax of America, INC. | $118.36 | 2020 | |
| Gilead Sciences, INC. | $101.63 | 2019-2023 | |
| Ardelyx, INC. | $99.80 | 2023-2024 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.04 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $91.54 | 2021-2023 | |
| Janssen Biotech, INC. | $85.80 | 2021-2024 | Stelara |
| Ironwood Pharmaceuticals, INC | $84.84 | 2021-2024 | Linzess |
| Exact Sciences Corporation | $84.37 | 2023 | Cologuard Collection Kit |
| Celgene Corporation | $79.45 | 2021-2022 | |
| Boston Scientific Corporation | $49.42 | 2020-2024 | Radial Jaw 4 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $37.42 | 2021 | |
| Redhill Biopharma INC. | $24.86 | 2020-2021 | |
| Daiichi Sankyo INC. | $23.38 | 2022 | |
| Celltrion USA INC. | $22.75 | 2023 | Yuflyma |
| Aimmune Therapeutics, INC. | $17.52 | 2024 | |
| Merck Sharp & Dohme LLC | $16.07 | 2021 | |
| Braintree Laboratories, INC. | $14.74 | 2019 | |
| Ucb, INC. | $14.21 | 2019 | |
| Mallinckrodt Hospital Products INC. | $13.71 | 2022 | |
| Allergan, INC. | $12.91 | 2019 | |
| Organon LLC | $12.77 | 2024 | |
| Shionogi INC | $12.73 | 2019 | |
| Evoke Pharma, INC. | $11.72 | 2021 | |
| Romark Laboratories, Lc | $4.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mckee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.